GPR37L1 and neuropathy: We postulate that dysregulation of GPR37L1/KCNJ10 signaling in SGCs in neuropathy conditions (CIPN and DPN) will impair the SGC’s function of K+ buffering, leading to sequential increases in extracellular levels of K+, nociceptor excitability, and pain sensitivity.